Pharmaceutical News

RSS

Leucine may help people burn fat during periods of food restriction

Research on Mt. Everest climbers is adding to the evidence that an amino acid called leucine - found in foods, dietary supplements, energy bars and other products - may help people burn fat during periods of food restriction, such as climbing at high altitude, while keeping their muscle tissue.

29 Aug 2011

One in three AF patients at high risk of stroke are not being prescribed VKA therapy

New data show that, worldwide, one in three patients with atrial fibrillation (AF) who are at high risk for stroke are not being prescribed anticoagulant therapy, particularly vitamin K antagonists (VKA) – medicines known to significantly lower stroke risk in these patients.

29 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

LUNGevity Foundation applauds the US Food and Drug Administration's (FDA) recent approval of XALKORI (crizotinib) to treat lung cancer. The drug, introduced by Pfizer, Inc. showed such promise in early trials that it was given "fast track" status by the FDA.

29 Aug 2011

Astellas seeks regulatory approval for mirabegron to treat overactive bladder in the U.S., Europe

Astellas Pharma Inc. today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron to the U.S. Food and Drug Administration and the European Medicines Agency.

29 Aug 2011

Researchers identify molecule that can stop the formation of amyloid fibrils

A molecule which can stop the formation of long protein strands, known as amyloid fibrils, that cause joint pain in kidney dialysis patients has been identified by researchers at the University of Leeds.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Nurofen mix up with Seroquel schizophrenia drug warns MHRA

British drug regulators have issued a safety alert on Thursday after discovering packs of the over-the-counter painkiller Nurofen Plus containing the anti-psychotic drug Seroquel XL.

26 Aug 2011

Autism link to vaccines dispelled by a large review of studies

According to a report issued by the US Institute of Medicine (IOM), vaccines are largely safe, and do not cause autism or diabetes. This conclusion followed a review of more than 1,000 published research studies.

26 Aug 2011

Rotavirus vaccine still effective in reducing diarrhea-related deaths in Mexico, researchers say

"The rotavirus vaccine introduced in Mexico in 2007 still appears to be preventing diarrhea-related deaths in children, despite speculation that years later the vaccine may not be as effective," according to the Los Angeles Times' "Booster Shots" blog.

26 Aug 2011

Viewpoints: Drug shortages = rationing; Changing forces in health marketplace; Birth control mandate

A widespread shortage of prescription drugs is hampering the treatment of patients who have cancer, severe infections and other serious illnesses. While some Republican politicians have railed against the imaginary threat of rationing under health care reform, Congress has done nothing to alleviate the all-too-real rationing of lifesaving drugs caused by this crisis.

26 Aug 2011

IOM report: Few health problems are clearly associated with vaccines

An analysis of more than 1,000 research articles concluded that few health problems are caused by or clearly associated with vaccines.

26 Aug 2011

Yale scientists synthesize huperzine A to combat Alzheimer's

Scientists at Yale University have developed the first practical method to create a compound called huperzine A in the lab.

26 Aug 2011

Google pays $500 million settlement in pharmacy ad probe

With the settlement, the Internet search engine will not face criminal prosecution related to accusations that it improperly benefited from ads promoting Canadian pharmacies that illegally imported medicines into the United States.

26 Aug 2011

Neoadjuvant chemotherapy prior to surgery can benefit women with lobular breast cancer

Researchers at the Medical University of Vienna have found that the breast of one in two women with lobular breast cancer can be preserved through chemotherapy prior to a breast operation.

26 Aug 2011

Researchers develop single vaccines to prevent rabies, Ebola infection

Researchers from Thomas Jefferson University, among other institutions, including the National Institute of Allergy and Infectious Diseases, have developed single vaccines to protect against both rabies and the Ebola virus.

26 Aug 2011

IOM issues new report on evidence and causality of vaccine harms

The Institute of Medicine's Panel on Adverse Effects of Vaccines issued a report today on the evidence and causality of vaccine harms. Despite a glowing press release, the report does little to allay public concerns over adverse effects of vaccines and suggests that we urgently need more science on vaccine adverse effects.

26 Aug 2011

Firazyr receives FDA approval for treatment of HAE acute attacks

The U.S. Food and Drug Administration today approved Firazyr (icatibant) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema (HAE) in people ages 18 years and older.

26 Aug 2011

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.

26 Aug 2011

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

26 Aug 2011